ArticleOncogene2014
ELF3 is a repressor of androgen receptor action in prostate cancer cells.
Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Transcriptomic analysis of castration, chemo-resistant and metastatic prostate cancer elucidates complex genetic crosstalk leading to disease progression.Functional & integrative genomics · 2021Pooled it
- Elf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer.Cell death & disease · 2014Trial
- Expression of Interferon Epsilon in Mucosal Epithelium is Regulated by Elf3.Molecular and cellular biology · 2024Article
- The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.Communications biology · 2023Article
- ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate.FEBS open bio · 2022Article
- Elf3 deficiency during zebrafish development alters extracellular matrix organization and disrupts tissue morphogenesis.PloS one · 2022Article
- Unique transcriptional signatures of sleep loss across independently evolved cavefish populations.Journal of experimental zoology. Part B, Molecular and developmental evolution · 2020Article
- Article
- Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.Nature communications · 2019Article
- Profiling of differentially expressed genes in cadmium-induced prostate carcinogenesis.Toxicology and applied pharmacology · 2019Article
- ELF3 is an antagonist of oncogenic-signalling-induced expression of EMT-TF ZEB1.Cancer biology & therapy · 2019Article
- ELF3, ELF5, EHF and SPDEF Transcription Factors in Tissue Homeostasis and Cancer.Molecules (Basel, Switzerland) · 2018Review
- Article
- Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.Cell reports · 2016Article
- Moonlighting proteins in cancer.Cancer letters · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
The androgen receptor (AR) has a critical role in the development and progression of prostate cancer (PC) and is a major therapeutic target in this disease. The transcriptional activity of AR is modulated by the coregulators with which it interacts, and consequently deregulation of cofactor expression and/or activity impacts the expression of genes whose products can have a role in PC pathogenesis. Here we report that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of AR transcriptional activity. Exogenous expression of ELF3 represses AR transcriptional activity when assessed using reporter-based transfection assays or when evaluated on endogenous AR target genes. Conversely, ELF3 knock down increases the AR transcriptional activity. Biochemical dissection of this activity indicates that it results from the physical interaction between ELF3 and AR and that this interaction inhibits the recruitment of AR to specific androgen response elements within target gene promoters. Significantly, we observed that depletion of ELF3 expression in LNCaP cells promotes cell migration, whereas increased ELF3 expression severely inhibits tumor growth in vitro and in a mouse xenograft model. Taken together, these results suggest that modulation of ELF3 expression and/or AR/ELF3 interaction may have utility in the treatment of PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.